Results 101 to 110 of about 8,134 (194)

Autosomal-dominante polyzystische Nierenerkrankung: Neue therapeutische Ansätze [PDF]

, 2018
Zusammenfassung: Die autosomal-dominante polyzystische Nierenerkrankung ("autosomal dominant polycystic kidney disease", ADPKD) ist die häufigste genetische Nierenerkrankung, sie betrifft weltweit etwa 6Mio. Menschen.
Poster, D., Serra, A.L., Wüthrich, R.P.
core  

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

Kidney International Reports
Introduction: Tolvaptan has been shown to reduce renal volume and delay disease progression in autosomal-dominant polycystic kidney disease (ADPKD). However, no biomarkers are currently available to guide dose adjustment.
F.J. Roca Oporto, C. Andrades Gómez, G. Montilla Cosano, A. Luna Aguilera, José L. Rocha   +4 more
doaj   +1 more source

The Vulnerable Phase of Heart Failure [PDF]

, 2018
Butler, Javed, Chioncel, Ovidiu, Collins, Sean, Gracia, Ely, Pang, Peter, Singh, Prabhjot   +5 more
core   +1 more source

Impact of continued administration of tolvaptan on cirrhotic patients with ascites [PDF]

, 2018
KODAMA Kazuhisa, KOGISO Tomomi, SAGAWA Takaomi, TANIAI Makiko, TOKUSHIGE Katsutoshi   +4 more
core   +2 more sources

The impact of tolvaptan on autosomal dominant polycystic kidney disease – literature review

Studia Medyczne
This article presents current data from international literature on the impact of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD). The authors have reviewed the latest clinical research literature.
Anna Gruszczyńska, Krzysztof Kowalik, Grażyna Dutkiewicz, Anna Rakoczy, Andrzej Modrzejewski   +4 more
doaj   +1 more source

Tolvaptan, a Selective Oral Vasopressin V2 -Receptor Antagonist, for Hyponatremia [PDF]

, 2018
Berl, Tomas, Czerwiec, Frank S., Gheorghiade, Mihai, Gross, Peter, Nagy, Endre V., Orlandi, Cesare, Schrier, Robert W., Verbalis, Joseph G.   +7 more
core   +1 more source

Insights into autosomal dominant polycystic kidney disease by quantitative mass spectrometry-based proteomics [PDF]

, 2018
Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenetic disorder that is caused by mutations in the genes PKD1 and PKD2 encoding polycystin-1 and polycystin-2, respectively.
Dengjel, Jörn, Diedrich, Britta
core  

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy [PDF]

, 2017
The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and ...
Bonventre, J, Coresh, J, Donner, J-A, Eckardt, K-U, Fogo, AB, Fox, CS, Gansevoort, RT, Heerspink, HJL, ISN Global Kidney Health Summit participants, Jardine, M, Kasiske, B, Kretzler, M, Köttgen, A, Levey, AS, Levin, A, Luyckx, VA, Mehta, R, Moe, O, Obrador, G, Pannu, N, Parikh, CR, Perkovic, V, Pollock, C, Stenvinkel, P, Tonelli, M, Tuttle, KR, Wheeler, DC   +26 more
core  

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. [PDF]

, 2017
Peters, S., Rizvi, N.A.
core   +1 more source

Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study. [PDF]

Front Med (Lausanne)
Zhou L, Li W.
europepmc   +1 more source